Markers of inflammation in schizophrenia: Association vs. causation

World Psychiatry

Volumn 13, Issue 2, 2014, Pages 189-192

  Manu, Peter ^a,b,c   Correll, Christoph U ^a,b,c   Wampers, Martien ^d   Mitchell, Alex J ^e,f   Probst, Michel ^d,g   Vancampfort, Davy ^d,g   De Hert, Marc ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

CROHN DISEASE; HUMAN; INFLAMMATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ULCERATIVE COLITIS;

EID: 84901759799     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20117     Document Type: Review

References (42)

1. Spelling B, Edwards JE Jr,. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32: 76-102.
2. Kirkpatrick B, Miller BJ,. Inflammation and schizophrenia. Schizophr Bull 2013; 39: 1174-9.
3. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-71.
4. Miller BJ, Culpepper N, Rapaport MH, et al. Prenatal inflammation and neuro-development in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 92-100.
5. Smith RS, Maes M,. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995; 45: 135-41.
6. Schwarz MJ, Muller N, Riedel M, et al. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001; 56: 483-6. (Pubitemid 32397883)
7. Busse S, Busse M, Schlitz K, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun 2012; 26: 1273-9.
8. Nitta M, Kishimoto T, Muller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013; 39: 1230-41.
9. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40: 181-91.
10. Keller WR, Kum LM, Wehring HJ, et al. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013; 27: 337-42.
11. Girgis RR, Kumar SS, Brown AS,. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014; 75: 292-9.
12. Howick J, Glasziou P, Aronson JK,. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009; 102: 186-94.
13. Arolt V, Weitzsch C, Wilke I, et al. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 1997; 66: 145-52. (Pubitemid 27085360)
14. Gaughran F, O'Neill E, Sham P, et al. Soluble interleukin-2 receptor levels in families of people with schizophrenia. Schizophr Res 2002; 56: 2235-9.
15. Martinez-Gras I, Garcia-Sanchez F, Guaza C, et al. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res 2012; 200: 1022-5.
16. Dimitrov DH, Lee S, Yantis J, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 2013; 151: 29-35.
17. Borovcanin M, Jovanovic I, Radosavljevic G, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation on the type-2 inflammatory response. Schizophr Res 2013; 147: 103-9.
18. Hope S, Ueland T, Steen NE, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013; 145: 36-42.
19. Ezeoke A, Mellor A, Buckley P, et al. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res 2013; 150: 245-51.
20. Benros ME, Pedersen MG, Rasmussen H, et al. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry (in press).
21. Howren MD, Lamkin DM, Suls J,. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-86.
22. Leonard BE,. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 261-7.
23. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
24. Hiles SA, Baker AL, de Malmanche T, et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 2012; 42: 2015-26.
25. Na KS, Lee KJ, Lee JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 79-85.
26. Serafini G, Pompili M, Elena-Serretti M, et al. The role of inflammatory cytokines in suicidal behavior: a systematic review. Eur Neuropsychopharmacol 2013; 23: 1672-86.
27. Hannestad J, DellaGioia N, Bloch M,. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36: 2452-9.
28. Maes M, Meltzer H, Jacobs J, et al. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr Scand 1993; 87: 160-6. (Pubitemid 23079925)
29. Horning M, Amsterdam JD, Kamoun M, et al. Autoantibody disturbances in affective disorders: a function of age and gender? J Affect Disord 1999; 55: 29-37. (Pubitemid 29412912)
30. Maes M,. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-75.
31. Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15-25.
32. Matsuzawa Y,. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42. (Pubitemid 43078211)
33. Jernas M, Palming J, Sjoholm K, et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 2006; 20: 1540-2.
34. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
35. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53. (Pubitemid 32756433)
36. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-Bank NF-xB. Nat Med 2005; 11: 183-90. (Pubitemid 40321354)
37. Hanssens L, van Winkel R, Wampers M, et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008; 106: 308-14.
38. Wampers M, Hanssens L, van Winkel R, et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2012; 22: 17-26.
39. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
40. Wager-Smith K, Markou A,. Depression: a repair response to stress induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev 2011; 35: 742-64.
41. Brydon L, Walker C, Wawrzyniak A, et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2004; 18: 458-67.
42. Deinzer R, Granrath N, Stuhl H, et al. Acute stress effects on local IL-1beta responses to pathogens in a human in vivo model. Brain Behav Immun 2004; 18: 458-67. (Pubitemid 38950841)